Emergence and evolution of TP53 mutations are a key feature of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

0 avis

Emergence and evolution of TP53 mutations are a key feature of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Archive ouverte

Edité par CCSD ; Ferrata Storti Foundation -

International audience. no abstract

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Archive ouverte | Vantyghem, Sophie | CCSD

International audience. Next generation sequencing (NGS) investigates for somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains challenging. We repor...

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia

Archive ouverte | Peterlin, Pierre | CCSD

International audience. Objective: This study was designed to assess the impact on outcomes of early soluble Fms-like tyrosine kinase 3 ligand concentrations (sFLc) in patients receiving an allogeneic hematopoietic ...

A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients

Archive ouverte | Boutault, Robin | CCSD

International audience

Chargement des enrichissements...